{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
ganciclovir
to a specific field?
There is one exact (name or code) match for ganciclovir
Status:
US Approved Rx
(2003)
Source:
ANDA076222
(2003)
Source URL:
First approved in 1989
Source:
CYTOVENE by CHEPLAPHARM
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Ganciclovir is a synthetic acyclic nucleoside analogue of 2'-deoxyguanosine active against cytomegalovirus. Ganciclovir has been shown to be active against cytomegalovirus (CMV) and herpes simplex virus (HSV) in humans. To achieve anti-CMV activity, ganciclovir is phosphorylated first to the monophosphate form by a CMV-encoded (UL97 gene) protein kinase homologue, then to the di- and triphosphate forms by cellular kinases. Ganciclovir triphosphate concentrations may be 100-fold greater in CMV-infected than in uninfected cells, indicating preferential phosphorylation in infected cells. Ganciclovir triphosphate, once formed, persists for days in the CMV-infected cell. Ganciclovir triphosphate is believed to inhibit viral DNA synthesis by (1) competitive inhibition of viral DNA polymerases; and (2) incorporation into viral DNA, resulting in eventual termination of viral DNA elongation. Ganciclovir is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS) and for the treatment of acute herpetic keratitis.
Status:
US Approved Rx
(2003)
Source:
ANDA076222
(2003)
Source URL:
First approved in 1989
Source:
CYTOVENE by CHEPLAPHARM
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Ganciclovir is a synthetic acyclic nucleoside analogue of 2'-deoxyguanosine active against cytomegalovirus. Ganciclovir has been shown to be active against cytomegalovirus (CMV) and herpes simplex virus (HSV) in humans. To achieve anti-CMV activity, ganciclovir is phosphorylated first to the monophosphate form by a CMV-encoded (UL97 gene) protein kinase homologue, then to the di- and triphosphate forms by cellular kinases. Ganciclovir triphosphate concentrations may be 100-fold greater in CMV-infected than in uninfected cells, indicating preferential phosphorylation in infected cells. Ganciclovir triphosphate, once formed, persists for days in the CMV-infected cell. Ganciclovir triphosphate is believed to inhibit viral DNA synthesis by (1) competitive inhibition of viral DNA polymerases; and (2) incorporation into viral DNA, resulting in eventual termination of viral DNA elongation. Ganciclovir is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS) and for the treatment of acute herpetic keratitis.
Status:
US Approved Rx
(2021)
Source:
NDA214460
(2021)
Source URL:
First approved in 1996
Source:
VISTIDE by GILEAD SCIENCES INC
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Cidofovir is an antiviral nucleotide analogue with significant activity against cytomegalovirus (CMV) and other herpesviruses. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis. Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis. Cidofovir is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome.
Status:
US Approved Rx
(1996)
Source:
NDA020629
(1996)
Source URL:
First approved in 1994
Source:
FAMVIR by NOVARTIS
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Penciclovir (DENAVIR®) is a synthetic acyclic guanine derivative with antiviral activity, mainly used to treat infections from herpes simplex virus (HSV) types 1 and 2. In cells infected with HSV-1 or HSV-2, the viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted by cellular kinases to the active form penciclovir triphosphate. Biochemical studies demonstrate that penciclovir triphosphate inhibits HSV polymerase competitively with deoxyguanosine triphosphate. Consequently, herpes viral DNA synthesis and, therefore, replication are selectively inhibited. Famciclovir (FAMVIR®) is a prodrug form of penciclovir with improved oral bioavailability.
Status:
US Approved Rx
(2021)
Source:
ANDA212483
(2021)
Source URL:
First approved in 1991
Source:
NDA020068
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Foscarnet is an antiviral agent. Foscarnet shows activity against human herpesviruses and HIV. Foscarnet is used for treating eye problems caused by CMV in people with AIDS. It is also used to treat a type of HSV that cannot be treated by another medicine in people with a weak immune system. FOSCAVIR is the brand name for foscarnet sodium. FOSCAVIR is an organic analogue of inorganic
pyrophosphate that inhibits replication of herpesviruses in
vitro including cytomegalovirus (CMV) and herpes simplex
virus types 1 and 2 (HSV-1 and HSV-2). FOSCAVIR exerts its antiviral activity by a selective
inhibition at the pyrophosphate binding site on virusspecific
DNA polymerases at concentrations that do not
affect cellular DNA polymerases. FOSCAVIR does not
require activation (phosphorylation) by thymidine kinase or
other kinases and therefore is active in vitro against HSV
TK deficient mutants and CMV UL97 mutants. Thus, HSV
strains resistant to acyclovir or CMV strains resistant to
ganciclovir may be sensitive to FOSCAVIR.
Status:
US Approved Rx
(2019)
Source:
ANDA210774
(2019)
Source URL:
First approved in 1982
Source:
NDA018604
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Acyclovir is a synthetic antiviral nucleoside analogue. A screening program for antiviral drugs begun at Burroughs Wellcome in the 1960s resulted in the discovery of acyclovir in 1974. Preclinical investigation brought the drug to clinical trials in 1977 and the first form of the drug (topical) was available to physicians in 1982. Activity of acyclovir is greatest against herpes 1 and herpes 2, less against varicella zoster, still less against Epstein-Barr, and very little against cytomegalovirus. Acyclovir is an antiviral agent only after it is phosphorylated in infected cells by a viral-induced thymidine kinase. Acyclovir monophosphate is phosphorylated to diphosphate and triphosphate forms by cellular enzymes in the infected host cell where the drug is concentrated. Acyclovir triphosphate inactivates viral deoxyribonucleic acid polymerase.
Status:
Investigational
Source:
Antimicrob Agents Chemother. Dec 1978;14(6):842-5.: Not Applicable Veterinary clinical trial Completed Keratitis
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
![Structure of 2-[[2-(Acetylamino)-6-oxo-1,6-dihydro-9H-purin-9-yl]methoxy]-3-hydroxypropyl acetate](/img/422f91fd-e252-49cb-851d-a9eb64970dac.svg?size=200&context=ckaidnrsfy)
![Structure of N-Methyl-L-valine 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester](/img/acd1e596-2f08-4e5b-ad2c-5c20401043ba.svg?size=200&context=ckaidnrsfy)